Baicalin-Liquiritin attenuates Cerebral Ischemia Reperfusion Injury via
Keap1-Nrf2/HO-1 signaling pathways
Abstract
Background and Purpose: Ischemic stroke is a complex neurological
diseases with limited therapeutic approaches. Baicalin-Liquiritin
(BA-LI) are effective components isolated from Scutellariae radix and
Glycyrrhiza glabra which possesses antioxidant and anti-inflammatory
properties. However, whether BA-LI has beneficial effects on ischemic
stroke as well as its underlying mechanism remains to be elucidated.
Experimental Approach: In order to investigate the protective effect of
BA-LI on ischemic stroke and its molecular mechanism, we constructed an
in vitro oxygen glucose deprivation/re-oxygenation (OGD/R) model as well
as the middle cerebral artery occlusion (MCAO/R) model and detected the
relevant indexes and the expression of Keap1-Nrf2/HO-1 signaling
pathways related proteins. Results: BA-LI could effectively reduce the
volume of cerebral infarction in MCAO/R mice, activate Keap/Nrf2
signaling, and the expression of anti-inflammatory factors TGF-β1 and
IL-10 was elevated after administration of BA-LI, and BA-LI had a
protective effect on cerebral ischemia/reperfusion injury in mice; in
vitro OGD/R model was constructed by using BV2 cells, and 5uM BA-LI was
able to significantly increase cell viability and down regulate Keap
protein expression, upregulated Nrf2 and HO-1 protein expression, and
increased the levels of M1 and M2 inflammatory factors IL-1β and TNF-α.
Conclusion: BA-LI attenuates cerebral ischemia reperfusion injury via
Keap1-Nrf2/HO-1 pathway, and is a promising novel therapeutic candidate
for ischemic stroke. Key Words: Ischemic stroke, Cerebral Ischemia
Reperfusion Injury,Baicalin, Liquiritin, Keap1-Nrf2/HO-1 signaling
pathways